These and our findings suggest that if PET/CT is used for response monitoring in HER2-positive breast cancer, it should evaluate both breast and axilla, and we recommend separate evaluation of both sites rather than an unconfirmed combined parameter as described above. This evidence concerns the gene ERBB2 and breast carcinoma.